Lucid Diagnostics Inc. (LUCD)
LUCDNASDAQ-CMMedical/Dental Instruments
$0.4170
0.0000 (0.00%) today
At the close, Nov 9, 4:00 PM ET. Pre-market $0.4182 +0.17%
- Market cap
- $85.00m
- P/E
- –
- EPS, last 4 quarters
- $-0.3800
- Dividend yield
- –
- Day range
- –
- 52-week range
- $0.3030 to $1.63
- Average volume
- 6.03m
- Previous close
- $0.4170
Analysts
5 coveringBuy5 buy, 0 hold, 0 sell
Targets a year out average $4.00, +859.2% from here
Earnings
next estimate $-0.0700Next report Nov 12, 2026
Sep 2025
-57.1%
Dec 2025
-37.5%
Mar 2026
-33.3%
Jun 2026
-60.0%
estimate reported, and the surprise
Financials
| Quarter | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| Revenue | $1.21m | $1.50m | $1.26m | $1.47m |
| Gross profit | -$485.0k | -$356.0k | -$369.0k | $29.0k |
| Operating income | -$11.76m | -$14.01m | -$12.11m | -$12.80m |
| Net income | -$10.40m | -$16.27m | -$13.91m | -$11.69m |
Last four quarters: revenue $5.45m, margin -959.8%, free cash flow -$47.18m
News
8 latest- Orthofix (OFIX) Surpasses Q3 Earnings EstimatesZacks · 21 hours ago
- Mettler-Toledo (MTD) Surpasses Q3 Earnings and Revenue EstimatesZacks · 4 days ago
- Biotech Stocks On Investor Radar - BOLT +66%, LYCA +33%, LUCD, GMAB RTTNews · Oct 23, 2026
- Lucid Shares Jump 40% Overnight On EsoGuard Medicare Payments, $15 Mln Financing RTTNews · Oct 22, 2026
- Lucid Diagnostics Inc. Closes $15.0 million Series C Preferred Stock OfferingFintel · Oct 22, 2026
- 3 Key Reasons to Buy This Huge Turnaround Story That's Gaining TractionThe Motley Fool · Oct 1, 2026
- Lucid Diagnostics (LUCD) Q2 2026 Earnings Call TranscriptThe Motley Fool · Aug 20, 2026
- Lucid Diagnostics Eyes Medicare Catalyst for EsoGuard GrowthMarketBeat · Aug 15, 2026
The company
Lucid Diagnostics Inc. is a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq: PAVM). Lucid is focused on the millions of patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, who are at risk of developing esophageal precancer and cancer. Lucid's EsoGuard Esophageal DNA Test, performed on samples collected in a brief, noninvasive office procedure with its EsoCheck Esophageal Cell Collection Device, represent the first and only commercially available tools designed with the goal of preventing cancer and cancer deaths through widespread, early detection of esophageal precancer in at-risk patients.
- Sector
- Health Care
- Industry
- Medical/Dental Instruments
- Exchange
- NASDAQ-CM
- Region
- North America
- Website
- luciddx.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.